Treatment for renal anemia and outcomes in non-dialysis patients with chronic kidney disease: the current status of regional medicine according to the Kyoto Fushimi Renal Anemia (KFRA) study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-019-01767-w
Abstract: The baseline data obtained in the CKD-JAC demonstrated that insufficient treatment was being provided for renal anemia by institutions specializing in renal disease. The objective of this study was to investigate the status of treatment… read more here.
Keywords: medicine; treatment renal; anemia; disease ... See more keywords
Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2021.174583
Abstract: Anemia is a common feature and complication of chronic kidney disease (CKD). Erythropoiesis-stimulating agents (ESAs) and recombinant human erythropoietin have been used widely in renal anemia treatment. Recently, hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) that… read more here.
Keywords: anemia; chronic kidney; factor; disease ... See more keywords
Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
Sign Up to like & getrecommendations! Published in 2021 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2021.07.015
Abstract: Introduction Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for renal anemia treatment, was evaluated in 5 phase 3 studies (MIYABI program). We report the results of the MIYABI hemodialysis-maintenance study. Methods This 52-week, randomized, double-blinded,… read more here.
Keywords: receiving dialysis; japanese patients; molidustat; molidustat darbepoetin ... See more keywords
Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.1c01479
Abstract: Activation of hypoxia-inducible factor 2 (HIF-2) has emerged as a potent renal anemia treatment strategy. Here, the benzisothiazole derivative 26 was discovered as a novel HIF-2α agonist, which first demonstrated nanomolar activity (EC50 = 490… read more here.
Keywords: anemia; factor hif; inducible factor; treatment ... See more keywords
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
Sign Up to like & getrecommendations! Published in 2019 at "Advances in chronic kidney disease"
DOI: 10.1053/j.ackd.2019.04.004
Abstract: Prolyl hydroxylase domain oxygen sensors are dioxygenases that regulate the activity of hypoxia-inducible factor (HIF), which controls renal and hepatic erythropoietin production and coordinates erythropoiesis with iron metabolism. Small molecule inhibitors of prolyl hydroxylase domain… read more here.
Keywords: current clinical; inducible factor; clinical experience; renal anemia ... See more keywords
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of nephrology"
DOI: 10.1159/000531084
Abstract: Renal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed… read more here.
Keywords: phd inhibitors; chronic kidney; hif phd; sglt2 inhibitors ... See more keywords
Exploring Mechanisms by Which Danggui Buxue Decoction Regulates Inflammation and Improves Renal Anemia Based on Network Pharmacology
Sign Up to like & getrecommendations! Published in 2022 at "Natural Product Communications"
DOI: 10.1177/1934578x221093905
Abstract: Background: Renal anemia occurs frequently in patients with chronic kidney disease (CKD) and is related to chronic inflammation. Danggui Buxue Decoction (DBD) can treat anemia and improve the chronic inflammation. However, whether DBD treatment attenuates… read more here.
Keywords: inflammation; network; dbd; pharmacology ... See more keywords
Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study
Sign Up to like & getrecommendations! Published in 2022 at "In Vivo"
DOI: 10.21873/invivo.12892
Abstract: Background/Aim: Renal anemia is a major complication in patients with chronic kidney disease (CKD) and hemodialysis, increasing morbidity and mortality. Roxadustat is a novel oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), which is administrated… read more here.
Keywords: inducible factor; hypoxia inducible; hemodialysis; treatment ... See more keywords
Enarodustat Treatment for Renal Anemia in Patients With Non-dialysis Chronic Kidney Disease
Sign Up to like & getrecommendations! Published in 2023 at "In Vivo"
DOI: 10.21873/invivo.13148
Abstract: Abstract Background/Aim: Renal anemia is a major complication in patients with chronic kidney disease (CKD), leading to morbidity and mortality. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHI), also called HIF stabilizers, increase endogenous erythropoietin production… read more here.
Keywords: patients non; non dialysis; renal anemia; treatment renal ... See more keywords
Administration of α-Klotho Does Not Rescue Renal Anemia in Mice
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.924915
Abstract: Renal anemia is a common complication in chronic kidney disease (CKD), associated with decreased production of erythropoietin (EPO) due to loss of kidney function, and subsequent decreased red blood cell (RBC) production. However, many other… read more here.
Keywords: iron; ckd; mice; anemia mice ... See more keywords
Tetramethylpyrazine nitrone activates hypoxia-inducible factor and regulates iron homeostasis to improve renal anemia
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.964234
Abstract: Renal anemia is one of the most common complications of chronic kidney disease and diabetic kidney disease. Despite the progress made in recent years, there is still an urgent unmet clinical need for renal anemia… read more here.
Keywords: inducible factor; tbn; hypoxia inducible; renal anemia ... See more keywords